bioMérieux S.A.
BMXXY | OTC
$10.19
+$0.21 (+2.10%)
At close: Oct 15, 2026, 2:40 PM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | 4.07B | 3.98B | 3.67B | 3.59B | 3.38B | 3.12B |
Cost of Revenue | 1.93B | 1.76B | 1.62B | 1.63B | 1.41B | 1.38B |
Gross Profit | 2.14B | 2.22B | 2.06B | 1.96B | 1.97B | 1.74B |
Operating Income | 561.2M | 588.8M | 439.1M | 559.8M | 768M | 551.2M |
Interest Income | 14.3M | 14.4M | 1.1M | 1.2M | 1.7M | 1.5M |
Pretax Income | 525.5M | 579.3M | 437.5M | 550.2M | 748.3M | 494.4M |
Net Income | 397.5M | 432.2M | 357.6M | 452.4M | 601.1M | 404.4M |
Selling & General & Admin | 1.11B | 1.1B | 1.02B | 954.7M | 815.6M | 789.3M |
Research & Development | 507.4M | 491.5M | 460.1M | 446.6M | 385.8M | 395.7M |
Other Expenses | -37.8M | 37.4M | 137.6M | n/a | n/a | n/a |
Operating Expenses | 1.58B | 1.63B | 1.62B | 1.4B | 1.2B | 1.19B |
Interest Expense | 15.8M | 16M | 4.4M | 4.1M | 9.1M | 24.9M |
Selling & Marketing Expenses | 791.2M | 783.8M | 725.5M | 701.5M | 573.5M | 589.3M |
Cost & Expenses | 3.51B | 3.39B | 3.23B | 3.03B | 2.61B | 2.57B |
Income Tax Expense | 128.8M | 154.3M | 114.5M | 109.7M | 149.4M | 91.5M |
Shares Outstanding (Basic) | 117.95M | 117.77M | 118.05M | 117.95M | 118.27M | 118.15M |
Shares Outstanding (Diluted) | 119.01M | 118.74M | 118.8M | 118.44M | 118.89M | 118.65M |
EPS (Basic) | 3.37 | 3.67 | 3.03 | 3.84 | 5.08 | 3.42 |
EPS (Diluted) | 3.34 | 3.64 | 3.01 | 3.82 | 5.06 | 3.41 |
EBITDA | 999.6M | 897.5M | 701.3M | 811.9M | 977.8M | 747.7M |
EBIT | 561.2M | 595.3M | 441.9M | 554.3M | 757.4M | 519.3M |
Depreciation & Amortization | 438.4M | 302.4M | 259.4M | 257.6M | 220.4M | 228.4M |
Add to Watchlist
Select watchlists to add or remove BMXXY